Mutual of America Capital Management LLC Trims Stake in Repligen Corporation $RGEN

Mutual of America Capital Management LLC lowered its stake in Repligen Corporation (NASDAQ:RGEN) by 2.8% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,171 shares of the biotechnology company’s stock after selling 833 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Repligen were worth $3,628,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Alliance Wealth Advisors LLC UT lifted its stake in Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 89 shares in the last quarter. State of Michigan Retirement System raised its holdings in Repligen by 0.8% in the 1st quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after acquiring an additional 100 shares during the last quarter. Louisiana State Employees Retirement System raised its holdings in Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after acquiring an additional 100 shares during the last quarter. State of Wyoming raised its holdings in Repligen by 5.2% in the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 115 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in Repligen by 65.3% in the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 128 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Transactions at Repligen

In related news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of Repligen in a report on Wednesday, September 3rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Repligen in a report on Wednesday, October 8th. Evercore ISI boosted their price target on Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. HSBC initiated coverage on Repligen in a report on Wednesday, October 1st. They issued a “buy” rating and a $150.00 price target for the company. Finally, Barclays boosted their price target on Repligen from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $169.62.

Repligen Trading Up 4.9%

RGEN stock opened at $165.20 on Friday. The company has a market cap of $9.29 billion, a price-to-earnings ratio of -660.77, a PEG ratio of 3.48 and a beta of 1.08. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The business has a fifty day simple moving average of $131.75 and a 200-day simple moving average of $127.38. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities research analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.